INVER GROVE HEIGHTS, Minn.--(BUSINESS WIRE)--June 14, 2006--MedicalCV, Inc. (OTCBB:MCVI - News) today announced that recent market conditions, coupled with the age of the financial statements included in its SEC filing, have delayed its proposed public offering. As previously disclosed, on May 19, 2006, the Company filed a registration statement on Form SB-2 with the Securities and Exchange Commission relating to a proposed public offering of approximately $30.0 million of common stock.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About MedicalCV
MedicalCV’s ATRILAZE surgical ablation system utilizes laser energy in cardiac tissue ablation procedures in open-heart surgery. The ATRILAZE system is currently being utilized as a potential means to treat atrial fibrillation in concomitant open-heart surgical procedures. Atrial fibrillation, or AF, is the most commonly occurring cardiac arrhythmia. It reduces cardiac output, is a major precursor to congestive heart failure and is associated with an increased incidence of stroke.
Contact: MedicalCV, Inc. Marc P. Flores, 651-452-3000 or EVC Group Investors: Doug Sherk, 415-896-6820 or Jennifer Beugelmans, 415-896-6820 jbeugelmans@evcgroup.com or Media: Steve DiMattia, 646-277-8706 sdimattia@evcgroup.com
Source: MedicalCV, Inc.
